High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Ebenbuild
Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company dedicated to addressing mitral valve disease through innovative technology. The company develops a proprietary device designed for both percutaneous catheter-based interventions and minimally invasive or open-heart surgical procedures. This novel device specifically targets the treatment of mitral valve regurgitation, aiming to restore proper mitral valve function in cases of both functional and degenerative conditions. By providing a new posterior surface for the anterior leaflet to seal effectively, Middle Peak Medical seeks to meet critical unmet needs in the management of mitral valve diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.